JP2004518699A - クエチアピンを用いた物質乱用の治療方法 - Google Patents

クエチアピンを用いた物質乱用の治療方法 Download PDF

Info

Publication number
JP2004518699A
JP2004518699A JP2002562353A JP2002562353A JP2004518699A JP 2004518699 A JP2004518699 A JP 2004518699A JP 2002562353 A JP2002562353 A JP 2002562353A JP 2002562353 A JP2002562353 A JP 2002562353A JP 2004518699 A JP2004518699 A JP 2004518699A
Authority
JP
Japan
Prior art keywords
quetiapine
substance
pharmaceutically acceptable
drug
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002562353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004518699A5 (xx
Inventor
シャーウッド・ブラウン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2004518699A publication Critical patent/JP2004518699A/ja
Publication of JP2004518699A5 publication Critical patent/JP2004518699A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2002562353A 2001-02-06 2002-02-05 クエチアピンを用いた物質乱用の治療方法 Pending JP2004518699A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26680801P 2001-02-06 2001-02-06
PCT/SE2002/000214 WO2002062346A1 (en) 2001-02-06 2002-02-05 Method of treating substance abuse with quetiapine

Publications (2)

Publication Number Publication Date
JP2004518699A true JP2004518699A (ja) 2004-06-24
JP2004518699A5 JP2004518699A5 (xx) 2005-12-22

Family

ID=23016078

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002562353A Pending JP2004518699A (ja) 2001-02-06 2002-02-05 クエチアピンを用いた物質乱用の治療方法

Country Status (8)

Country Link
US (2) US7304047B2 (xx)
EP (1) EP1359919B1 (xx)
JP (1) JP2004518699A (xx)
AT (1) ATE360425T1 (xx)
DE (1) DE60219761T2 (xx)
ES (1) ES2284830T3 (xx)
HK (1) HK1059391A1 (xx)
WO (1) WO2002062346A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
JP2008526839A (ja) * 2005-01-07 2008-07-24 アストラゼネカ・アクチエボラーグ １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
CN101610774B (zh) * 2006-11-03 2012-04-04 萨斯喀彻温大学 治疗脱髓鞘疾病的方法
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
US11545173B2 (en) * 2018-08-31 2023-01-03 The Regents Of The University Of Michigan Automatic speech-based longitudinal emotion and mood recognition for mental health treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
TW587938B (en) 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
WO2000071106A2 (en) 1999-05-19 2000-11-30 Astrazeneca Ab Method of treating weight gain

Also Published As

Publication number Publication date
US20040058910A1 (en) 2004-03-25
DE60219761T2 (de) 2008-01-17
WO2002062346A1 (en) 2002-08-15
DE60219761D1 (de) 2007-06-06
EP1359919A1 (en) 2003-11-12
EP1359919B1 (en) 2007-04-25
ATE360425T1 (de) 2007-05-15
ES2284830T3 (es) 2007-11-16
US20070249582A1 (en) 2007-10-25
US7304047B2 (en) 2007-12-04
HK1059391A1 (en) 2004-07-02

Similar Documents

Publication Publication Date Title
EP1948177B1 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US11813248B2 (en) NK-1 antagonist compositions and methods for use in treating depression
JPH0635382B2 (ja) 抗不安薬としてのフルオキセチンの使用法
KR100712570B1 (ko) 알콜 의존성 치료약의 제조에서 플루마제닐의 용도
US20070249582A1 (en) Method of Treating Substance Abuse with Quetiapine
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
JP6499634B2 (ja) 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ
US20080108597A1 (en) New Use of Quetiapine
US6653339B2 (en) Method of treating irritable bowel syndrome
JP3243514B2 (ja) 療法―抵抗性精神分裂症治療用医薬
EP1795199A2 (en) Quetiapine for the treatment of substance dependence or substance abuse
JP2014513689A (ja) 過活動膀胱の治療のためのトロスピウムと唾液分泌刺激剤の組合せ
CN115607545B (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
CA2363784A1 (en) Method of treatment
HUT71466A (en) Pharmaceutical compositions for inhibition of obsessive-compulsive and consumptive disorders containing 2-phenyl-3-aroyl-benzothiophene-derivatives and process for their preparation
KR20240006600A (ko) 투약 요법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090324